Galaxy Macau Phase 2

Codiak BioSciences Inc (NASDAQ: CDAK) announced initial data for exoSTING currently in a Phase 1/2 trial as a single agent for the treatment of multiple solid tumors. ExoSTING is an engineered exosome therapeutic candidate. In the first three dose cohorts of the trial, participants...

In the past six weeks, Citi analyst Anil Daswani has met with more than 100 institutional investors from around the world to discuss the outlook for Macau gaming stocks. According to Daswani, investors are still cautious on Macau, but many admit that the long-term free cash flow (FCF) story is...